Drug Profile
Roquinimex - Pfizer
Alternative Names: FCF 89; Linomide; LS 2616Latest Information Update: 25 Sep 2006
Price :
$50
*
At a glance
- Originator Pfizer
- Class Hydroxyquinolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Diabetic complications; Gastrointestinal cancer; Hairy cell leukaemia; Leukaemia; Liver disorders; Malignant melanoma; Multiple sclerosis; Prostate cancer; Renal cancer; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 25 Sep 2006 Discontinued - Clinical-Phase-Unknown for Chronic myeloid leukaemia in USA (unspecified route)
- 25 Sep 2006 Discontinued - Phase-I for Acute myeloid leukaemia in Sweden (PO)
- 25 Sep 2006 Discontinued - Phase-I for Gastrointestinal cancer in Sweden (PO)